By Billy Candra 
The decision to initiate hormone therapy (HT) during the menopause transition, a pivotal life phase marking the cessation of a woman’s menstrual cycle, has long been a subject of intense scientific and public debate. While hormone replacement is widely recommended for managing debilitating menopausal symptoms such as hot flashes and night sweats, persistent confusion has surrounded its long-term effects, particularly concerning cardiovascular health. However, a significant new study, spearheaded by Matthew Nudy, assistant professor of medicine at the Penn State College of Medicine, suggests that long-term use of estrogen-based hormone therapies may offer beneficial effects on heart health, notably by improving key cardiovascular biomarkers.
The Evolving Landscape of Menopause and Hormone Therapy
Menopause is a natural biological process that typically occurs between the ages of 45 and 55, with the average age being 51 in the United States. It marks the end of a woman’s reproductive years, confirmed after 12 consecutive months without a menstrual period. This transition is characterized by fluctuating and ultimately declining levels of reproductive hormones, primarily estrogen and progesterone, leading to a myriad of symptoms that can range from mild to severely disruptive. Beyond the commonly recognized hot flashes, night sweats, and vaginal dryness, the hormonal shifts of menopause also usher in a less obvious but profoundly significant change: an increased risk of cardiovascular disease (CVD). The decline in estrogen, a hormone known for its protective effects on the cardiovascular system, can lead to adverse changes in cholesterol profiles, blood pressure regulation, and an accelerated buildup of plaque in blood vessels, collectively elevating the risk of heart attack and stroke.
For decades, hormone therapy—the practice of supplementing the body with synthetic or bioidentical hormones to replace those that are no longer produced—was a cornerstone of menopausal care. Its popularity soared in the mid-20th century, with many women taking HT for extended periods, believing it offered not only symptom relief but also protection against heart disease and osteoporosis. However, the landscape dramatically shifted in 2002 with the publication of initial findings from the Women’s Health Initiative (WHI), a large-scale, long-term national study funded by the National Institutes of Health (NIH) focusing on postmenopausal women. The WHI’s initial reports, particularly concerning the estrogen-plus-progestin arm, suggested an increased risk of breast cancer, heart attacks, strokes, and blood clots in women taking HT, leading to a precipitous decline in HT prescriptions and widespread public alarm.
The WHI findings, while groundbreaking, also sparked intense re-evaluation and subsequent analyses. Over the past two decades, a more nuanced understanding has emerged, often referred to as the "timing hypothesis." This hypothesis posits that the age at which HT is initiated, and the duration since menopause onset, significantly influence its risk-benefit profile. Specifically, it suggests that HT may be safer and more beneficial for younger menopausal women (typically under 60 or within 10 years of menopause onset) who are generally healthy and have no pre-existing cardiovascular disease. For these women, HT is often seen as an effective strategy for managing bothersome menopausal symptoms without significantly increasing cardiovascular risks, and potentially offering some benefits.
A Deeper Dive into Cardiovascular Biomarkers
Against this complex backdrop, the new multi-institutional study led by Dr. Nudy sought to clarify the long-term effects of hormone therapy on cardiovascular health, specifically by analyzing key biomarkers. While prior research often focused on short-term effects, this study provided a unique six-year longitudinal perspective. The research team meticulously analyzed data from hormone therapy clinical trials that were integral parts of the WHI, focusing on a subset of women who had participated in an oral hormone therapy clinical trial.
The study participants, comprising 2,696 postmenopausal women aged 50 to 79 at the time of assignment, were randomly allocated to one of two oral hormone therapy groups: an estrogen-only group (for women who had undergone a hysterectomy) or an estrogen-plus-progesterone group (for women with an intact uterus). Blood samples were collected at baseline and then at one, three, and six years, allowing for a comprehensive assessment of changes in cardiovascular biomarkers over time. This cohort represented approximately 10% of the total trial participants, providing a robust dataset for analysis.
The findings, published in the journal Obstetrics & Gynecology, revealed several beneficial effects on cardiovascular biomarkers. In both the estrogen-only and estrogen-plus-progesterone groups, levels of LDL cholesterol, often dubbed "bad cholesterol" due to its association with plaque buildup in arteries, were reduced by approximately 11%. Total cholesterol and measures of insulin resistance also decreased in both groups, indicating improved metabolic health. Conversely, HDL cholesterol, the "good cholesterol" known for its role in transporting excess cholesterol away from arteries, increased by 13% in the estrogen-only group and 7% in the estrogen-plus-progesterone group. These changes collectively suggest a more favorable lipid profile and potentially reduced atherosclerotic risk.
However, the study also observed increases in triglycerides, another type of fat in the blood, and coagulation factors, which are proteins involved in blood clot formation. These findings are consistent with some previous research on oral estrogen therapy and underscore the need to consider the full spectrum of effects.
The Unanticipated Breakthrough: Lipoprotein(a) Reduction
Perhaps the most striking and surprising discovery from Dr. Nudy’s team was the significant reduction in levels of lipoprotein(a), or Lp(a). Lp(a) is a type of cholesterol molecule whose concentrations are primarily determined by genetics, largely uninfluenced by lifestyle factors such as diet or exercise, which typically impact other cholesterol levels. Patients with high Lp(a) concentrations face a substantially increased risk of heart attack and stroke, often at a younger age, and are also at a higher risk for aortic stenosis, a serious condition involving calcium buildup on a heart valve.
The study found that Lp(a) levels decreased by 15% in the estrogen-only group and a remarkable 20% in the estrogen-plus-progesterone group. "As a cardiologist, this finding is the most interesting aspect of this research," Dr. Nudy stated, highlighting its profound clinical significance. "Currently, there are no medications approved by the Food and Drug Administration (FDA) specifically to lower lipoprotein(a). Here, we essentially found that oral hormone therapy significantly reduced lipoprotein(a) concentrations over the long-term." This discovery opens a new avenue for potentially mitigating a stubborn and largely untreatable cardiovascular risk factor.
Further analysis of the data by self-reported racial and ethnic group revealed even more pronounced decreases in Lp(a) concentration among participants with American Indian or Alaska Native ancestry (a 41% reduction) and Asian or Pacific Islander ancestry (a 38% reduction). While the precise reasons for these steeper reductions remain unclear, Dr. Nudy and his team hope to investigate these demographic differences in future research, potentially uncovering critical insights into personalized medicine approaches.
Formulations and Future Directions
Dr. Nudy noted that the estrogen therapy administered in the clinical trial was conjugated equine estrogens (CEE), a commonly prescribed form of oral estrogen therapy. A key characteristic of oral hormone therapy is its "first-pass metabolism" through the liver before it is absorbed into the bloodstream. This hepatic processing can sometimes lead to an increase in inflammatory markers, which may account for the observed rise in triglycerides and coagulation factors in the study.
This distinction is crucial when considering different routes of HT administration. "There are now other common formulations of estrogen hormone therapy like transdermal estrogen, which is administered through the skin," Dr. Nudy explained. "Newer studies have found that transdermal estrogen doesn’t increase triglycerides, coagulation factors or inflammatory markers." This highlights that the mode of delivery can significantly impact the metabolic and cardiovascular effects of hormone therapy, suggesting that transdermal options might offer a more favorable profile for some women, particularly those with concerns about triglyceride levels or clotting risk.
The implications of this research are substantial. It reinforces the evolving consensus that for healthy women within 10 years of menopause onset, HT can be a safe and effective option for symptom management, with potential long-term cardiovascular benefits. The finding regarding Lp(a) is particularly groundbreaking, offering a potential therapeutic strategy for a high-risk population currently lacking targeted treatments. However, Dr. Nudy emphasized that "Currently, hormone therapy is not FDA-approved to reduce the risk of coronary artery disease or stroke." This underscores that HT should primarily be considered for symptom relief, with the cardiovascular benefits being a significant, but secondary, finding.
For individuals contemplating menopause hormone therapy, Dr. Nudy strongly recommends undergoing a comprehensive cardiovascular disease risk assessment. This assessment is vital even if a person has no prior history of heart attack or stroke, or has not been diagnosed with cardiovascular disease. Such an evaluation provides healthcare providers with crucial information, enabling them to engage in shared decision-making with patients to determine the most appropriate and personalized treatment option for managing menopausal symptoms while considering overall health risks and benefits.
This study, supported by funding from the National Center for Advancing Translational Sciences, adds a vital piece to the intricate puzzle of hormone therapy and heart health. It underscores the complexity of medical decision-making in menopause and the continuous need for rigorous scientific inquiry to provide women and their healthcare providers with the clearest possible guidance. The collaborative effort involved a multi-institutional team of researchers, including Aaron Aragaki from Fred Hutchinson Cancer Center; Peter Schnatz and Xuezhi Jiang from Drexel University College of Medicine; JoAnn Manson from Brigham and Women’s Hospital, Harvard Medical School and Harvard T.H. Chan School of Public Health; Aladdin Shadyab from University of California San Diego; Su Yong Jung from University of California Los Angeles; Lisa Martin from The George Washington University; Robert Wild from University of Oklahoma Health Sciences Center; Catherine Womack from University of Tennessee Health Science Center; Charles Mouton from University of Texas Medical Branch; and Jacques Rossouw, formerly of the National Heart, Lung, and Blood Institute at the National Institutes of Health. Their combined expertise has significantly advanced the understanding of this critical area of women’s health.
